|Bid||1.95 x 700|
|Ask||2.00 x 6100|
|Day's Range||1.91 - 2.00|
|52 Week Range||1.75 - 6.40|
|PE Ratio (TTM)||15.67|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
SOUTH SAN FRANCISCO, Calif., July 6, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with Walter Reed Army Institute of Research (WRAIR) and Southwest Research Institute (SwRI) to evaluate the development of ProNeura-based implants for a long-term regimen in the prevention of malaria.
The article discusses how "pharmaceutical implants, matchstick-size devices that deliver drugs to patients over a period of weeks or months, are coming into their own." Specifically, the article highlights Titan's FDA-approved Probuphine® (buprenorphine) implant product, which treats opioid addiction by providing continuous doses of buprenorphine for up to six months, and that is being commercialized in the United States by its partner, Braeburn Pharmaceuticals, as well as Titan's development of its ProNeura implantable technology for Parkinson's disease.
Q1 2017 Titan Pharmaceuticals Inc Earnings Call